Moberg Pharma (Sweden) Performance
| MOB Stock | SEK 7.81 0.20 2.50% |
The company secures a Beta (Market Risk) of 0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Moberg Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Moberg Pharma is expected to be smaller as well. At this point, Moberg Pharma AB has a negative expected return of -0.44%. Please make sure to verify Moberg Pharma's potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Moberg Pharma AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Moberg Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 29.3 M | |
| Total Cashflows From Investing Activities | -41.3 M |
Moberg |
Moberg Pharma Relative Risk vs. Return Landscape
If you would invest 1,050 in Moberg Pharma AB on December 22, 2024 and sell it today you would lose (269.00) from holding Moberg Pharma AB or give up 25.62% of portfolio value over 90 days. Moberg Pharma AB is producing return of less than zero assuming 3.3385% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than Moberg Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Moberg Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moberg Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moberg Pharma AB, and traders can use it to determine the average amount a Moberg Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MOB |
Estimated Market Risk
| 3.34 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.44 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Moberg Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moberg Pharma by adding Moberg Pharma to a well-diversified portfolio.
Moberg Pharma Fundamentals Growth
Moberg Stock prices reflect investors' perceptions of the future prospects and financial health of Moberg Pharma, and Moberg Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moberg Stock performance.
| Return On Equity | -0.0325 | |||
| Return On Asset | -0.0249 | |||
| Operating Margin | (97.71) % | |||
| Current Valuation | 82.88 M | |||
| Shares Outstanding | 98.27 M | |||
| Price To Earning | 4.77 X | |||
| Price To Book | 0.42 X | |||
| Price To Sales | 1,098 X | |||
| Revenue | 209.68 M | |||
| EBITDA | 6.46 M | |||
| Cash And Equivalents | 36.6 M | |||
| Cash Per Share | 2.82 X | |||
| Total Debt | 16.25 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 5.43 X | |||
| Cash Flow From Operations | (15.3 M) | |||
| Earnings Per Share | (0.36) X | |||
| Total Asset | 450.89 M | |||
| Retained Earnings | (65 M) | |||
| Current Asset | 410 M | |||
| Current Liabilities | 50 M | |||
About Moberg Pharma Performance
Assessing Moberg Pharma's fundamental ratios provides investors with valuable insights into Moberg Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Moberg Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Moberg Pharma AB , a pharmaceutical company, develops and commercializes medical products for pain and skin conditions in Europe, the United States, and internationally. Moberg Pharma AB was incorporated in 2006 and is headquartered in Bromma, Sweden. Moberg Pharma operates under Drug ManufacturersSpecialty Generic classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.Things to note about Moberg Pharma AB performance evaluation
Checking the ongoing alerts about Moberg Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moberg Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moberg Pharma AB generated a negative expected return over the last 90 days | |
| Moberg Pharma AB has high historical volatility and very poor performance | |
| Moberg Pharma AB has accumulated about 36.6 M in cash with (15.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.82. | |
| Roughly 18.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Moberg Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moberg Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Moberg Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moberg Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moberg Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moberg Pharma's stock. These opinions can provide insight into Moberg Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Moberg Stock Analysis
When running Moberg Pharma's price analysis, check to measure Moberg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moberg Pharma is operating at the current time. Most of Moberg Pharma's value examination focuses on studying past and present price action to predict the probability of Moberg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moberg Pharma's price. Additionally, you may evaluate how the addition of Moberg Pharma to your portfolios can decrease your overall portfolio volatility.